These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18775075)

  • 61. A Machine Learning Approach for the Discovery of Ligand-Specific Functional Mechanisms of GPCRs.
    Plante A; Shore DM; Morra G; Khelashvili G; Weinstein H
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31159491
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Structure-based drug screening for G-protein-coupled receptors.
    Shoichet BK; Kobilka BK
    Trends Pharmacol Sci; 2012 May; 33(5):268-72. PubMed ID: 22503476
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessing GPCR homology models constructed from templates of various transmembrane sequence identities: Binding mode prediction and docking enrichment.
    Loo JSE; Emtage AL; Ng KW; Yong ASJ; Doughty SW
    J Mol Graph Model; 2018 Mar; 80():38-47. PubMed ID: 29306746
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Extended template-based modeling and evaluation method using consensus of binding mode of GPCRs for virtual screening.
    Sato M; Hirokawa T
    J Chem Inf Model; 2014 Nov; 54(11):3153-61. PubMed ID: 25350693
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists.
    Kolb P; Phan K; Gao ZG; Marko AC; Sali A; Jacobson KA
    PLoS One; 2012; 7(11):e49910. PubMed ID: 23185482
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Applications of machine learning in GPCR bioactive ligand discovery.
    Jabeen A; Ranganathan S
    Curr Opin Struct Biol; 2019 Apr; 55():66-76. PubMed ID: 31005679
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rough set-based proteochemometrics modeling of G-protein-coupled receptor-ligand interactions.
    Strömbergsson H; Prusis P; Midelfart H; Lapinsh M; Wikberg JE; Komorowski J
    Proteins; 2006 Apr; 63(1):24-34. PubMed ID: 16435365
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Automatic clustering of docking poses in virtual screening process using self-organizing map.
    Bouvier G; Evrard-Todeschi N; Girault JP; Bertho G
    Bioinformatics; 2010 Jan; 26(1):53-60. PubMed ID: 19910307
    [TBL] [Abstract][Full Text] [Related]  

  • 69. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
    Heilker R; Wolff M; Tautermann CS; Bieler M
    Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
    [TBL] [Abstract][Full Text] [Related]  

  • 70. GGIP: Structure and sequence-based GPCR-GPCR interaction pair predictor.
    Nemoto W; Yamanishi Y; Limviphuvadh V; Saito A; Toh H
    Proteins; 2016 Sep; 84(9):1224-33. PubMed ID: 27191053
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Docking and Virtual Screening Strategies for GPCR Drug Discovery.
    Beuming T; Lenselink B; Pala D; McRobb F; Repasky M; Sherman W
    Methods Mol Biol; 2015; 1335():251-76. PubMed ID: 26260606
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Active learning for computational chemogenomics.
    Reker D; Schneider P; Schneider G; Brown JB
    Future Med Chem; 2017 Mar; 9(4):381-402. PubMed ID: 28263088
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hierarchical analysis of the target-based scoring function modification for the example of selected class A GPCRs.
    Rzęsikowska K; Kalinowska-Tłuścik J; Krawczuk A
    Phys Chem Chem Phys; 2023 Jan; 25(4):3513-3520. PubMed ID: 36637161
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interacting with GPCRs: Using Interaction Fingerprints for Virtual Screening.
    Lenselink EB; Jespers W; van Vlijmen HW; IJzerman AP; van Westen GJ
    J Chem Inf Model; 2016 Oct; 56(10):2053-2060. PubMed ID: 27626908
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Development and application of hybrid structure based method for efficient screening of ligands binding to G-protein coupled receptors.
    Kortagere S; Welsh WJ
    J Comput Aided Mol Des; 2006 Dec; 20(12):789-802. PubMed ID: 17054015
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A machine learning model for classifying G-protein-coupled receptors as agonists or antagonists.
    Oh J; Ceong HT; Na D; Park C
    BMC Bioinformatics; 2022 Aug; 23(Suppl 9):346. PubMed ID: 35982407
    [TBL] [Abstract][Full Text] [Related]  

  • 77. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
    Sriram K; Insel PA
    Mol Pharmacol; 2018 Apr; 93(4):251-258. PubMed ID: 29298813
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function.
    Kristiansen K
    Pharmacol Ther; 2004 Jul; 103(1):21-80. PubMed ID: 15251227
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Virtual screen for ligands of orphan G protein-coupled receptors.
    Bock JR; Gough DA
    J Chem Inf Model; 2005; 45(5):1402-14. PubMed ID: 16180917
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Importance of protein dynamics in the structure-based drug discovery of class A G protein-coupled receptors (GPCRs).
    Lee Y; Lazim R; Macalino SJY; Choi S
    Curr Opin Struct Biol; 2019 Apr; 55():147-153. PubMed ID: 31102980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.